These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34494979)

  • 1. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
    Fajac I; Sermet I
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
    Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New horizons for cystic fibrosis treatment.
    Fajac I; De Boeck K
    Pharmacol Ther; 2017 Feb; 170():205-211. PubMed ID: 27916649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule drugs for cystic fibrosis: Where are we now?
    Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
    Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide-based therapies for cystic fibrosis.
    Kreda SM
    Curr Opin Pharmacol; 2022 Oct; 66():102271. PubMed ID: 35988291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis.
    Clarke LA; Luz VCC; Targowski S; Ramalho SS; Farinha CM; Amaral MD
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis.
    Thakur S; Ankita ; Dash S; Verma R; Kaur C; Kumar R; Mazumder A; Singh G
    Cell Biochem Biophys; 2024 Mar; 82(1):15-34. PubMed ID: 38048024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.
    Sloane PA; Rowe SM
    Curr Opin Pulm Med; 2010 Nov; 16(6):591-7. PubMed ID: 20829696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.